Pliant Therapeutics, Inc.: Focused on treatments for fibrotic diseases by harnessing the therapeutic potential of integrin biology and TGF-β modulation. Lead program is a small molecule dual selective inhibitor of avb6/avb1 integrins for IPF, primary sclerosing cholangitis (PSC), and renal fibrosis - received orphan drug designation and will enter Ph1 in December 2018. Second program is a selective avb1 inhibitor for the treatment of end stage liver fibrosis and has entered into development candidate selection.
260 Littlefield Avenue
South San Francisco, CA 94080

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.